Skip to main content
An official website of the United States government
Grant Details

Grant Number: 1R01CA218155-01 Interpret this number
Primary Investigator: Graetz, Ilana
Organization: University Of Tennessee Health Sci Ctr
Project Title: Communication App to Manage Symptoms and Improve Adjuvant Endocrine Therapy Adherence
Fiscal Year: 2017


Abstract

For women with hormone receptor-positive breast cancer, long-term use of adjuvant endocrine therapy (AET) significantly reduces the risk of hospitalizations, cancer recurrence and mortality, and increases quality of life. Despite the known benefits of AETs, many patients are nonadherent due to adverse side effects. Furthermore, lower adherence among black women may be contributing to the large and growing disparities in mortality outcomes. Real-time monitoring of treatment-related adverse symptoms and adherence could result in more effective management of symptoms, higher medication adherence, and ultimately lower recurrence and mortality. To date, however, only a few interventions have aimed to improve AET adherence, few have targeted symptom management as a means to improve adherence, and of these, none have found a statistically significant impact on adherence. Our proposed study will fill this research gap by testing a web- enabled app designed with the explicit goal of improving long-term AET adherence. Patient-reported symptoms will be integrated directly with the patient's electronic health record in order to improve patient-provider communication about AET adherence and related adverse symptoms outside of clinic visits. In a small pilot trial of the study app, we found that participants who had recently initiated a new AET and received weekly reminders to use the app reported significantly higher adherence to AETs at 8 weeks compared with a control group (91% vs. 68%, p=0.02). The proposed study builds on the success of our pilot study by: 1) expanding the intervention period to six months in order to capture later-onset adverse symptoms that are slower to develop; 2) following participants for one to three years, depending on enrollment year, to test longer-term effects of the intervention on medication adherence and other outcomes; and 3) including a larger sample powered to test multiple levels of the intervention. We will randomize 300 participants to one of three arms: 1) an “App” group (n=100) that will receive weekly reminders to use the PCM app; 2) an “App+Feedback” group (n=100) that will receive weekly reminders and personalized feedback based on their use of the app; or 3) a “Usual Care” group (n=100) that will receive usual care only. The app will include questions about AET adherence and adverse symptoms with built-in alerts sent to the patient's care team if any concerning symptoms or trends are reported. We hypothesize that monitoring symptoms and adherence with actionable alerts and tailored feedback reports to patients will result in timelier symptom management and higher long- term adherence to AET. By evaluating the impact of the intervention on a comprehensive set of measures, including AET adherence, patient outcomes, racial disparities and resource use-related costs, our study will provide valuable and actionable results for providers, policy makers, and insurers who strive to achieve the “Triple Aim” – reduce costs while improving health outcomes and the patient experience.



Publications

Remote Monitoring and Self-Efficacy: Implications for Breast Cancer Survivorship Outcomes.
Authors: Graetz I. , Hernandez S. , Hu X. , Krukowski R.A. , Vidal G.A. , Schwartzberg L.S. .
Source: The American Journal Of Managed Care, 2026 Aug; 32(8), p. 437-443.
PMID: 42663546
Related Citations

Adherence to oral endocrine therapy by menopausal status: post hoc insights from a remote monitoring randomized trial.
Authors: Graetz I. , Hu X. , Krukowski R.A. , Anderson J.N. , Stepanski E. , Vidal G. , Waters T.M. , Schwartzberg L.S. .
Source: Npj Breast Cancer, 2026-01-28 00:00:00.0; , .
EPub date: 2026-01-28 00:00:00.0.
PMID: 41605963
Related Citations

Potential role of perceived discrimination and sociodemographics on racial disparities in breast cancer symptom burden.
Authors: Hu X. , Cai C. , Arshad S. , Anderson J.N. , Torres M.A. , Vidal G.A. , Schwartzberg L. , Graetz I. .
Source: Journal Of The National Cancer Institute, 2025-12-09 00:00:00.0; , .
EPub date: 2025-12-09 00:00:00.0.
PMID: 41360078
Related Citations

Racial Differences in Symptom Burden and Endocrine Therapy Adherence in Breast Cancer: A Post Hoc Analysis of a Randomized Trial.
Authors: Hu X. , Krukowski R.A. , Stepanski E. , Anderson J.N. , Vidal G.A. , Torres M.A. , Schwartzberg L.S. , Graetz I. .
Source: Journal Of The National Comprehensive Cancer Network : Jnccn, 2025-09-26 00:00:00.0; 23(10), .
EPub date: 2025-09-26 00:00:00.0.
PMID: 41005350
Related Citations

Perceived discrimination, patient-provider communication, and quality of life among breast cancer survivors: a mediation analysis.
Authors: Yang F. , Hu X. , Anderson J.N. , Vidal G.A. , Stepanski E. , Schwartzberg L.S. , Graetz I. .
Source: Journal Of Cancer Survivorship : Research And Practice, 2025-08-28 00:00:00.0; , .
EPub date: 2025-08-28 00:00:00.0.
PMID: 40875141
Related Citations

COVID-19-Related Financial Hardship and Adherence to Adjuvant Endocrine Therapy Among Women With Early-Stage Breast Cancer.
Authors: Arshad S. , Hu X. , Krukowski R.A. , Waters T.M. , Vidal G.A. , Schwartzberg L. , Lipscomb J. , Graetz I. .
Source: Health Services Research, 2025-06-17 00:00:00.0; , p. e14658.
EPub date: 2025-06-17 00:00:00.0.
PMID: 40525537
Related Citations

Symptom Monitoring App Use Associated With Medication Adherence Among Woman Survivors of Breast Cancer on Adjuvant Endocrine Therapy.
Authors: Krukowski R.A. , Hu X. , Arshad S. , Anderson J.N. , Stepanski E. , Vidal G.A. , Schwartzberg L.S. , Graetz I. .
Source: Jco Clinical Cancer Informatics, 2024 Dec; 8, p. e2400179.
EPub date: 2024-12-06 00:00:00.0.
PMID: 39642329
Related Citations

Remote Monitoring App for Endocrine Therapy Adherence Among Patients With Early-Stage Breast Cancer: A Randomized Clinical Trial.
Authors: Graetz I. , Hu X. , Kocak M. , Krukowski R.A. , Anderson J.N. , Waters T.M. , Curry A.N. , Robles A. , Paladino A. , Stepanski E. , et al. .
Source: Jama Network Open, 2024-06-03 00:00:00.0; 7(6), p. e2417873.
EPub date: 2024-06-03 00:00:00.0.
PMID: 38935379
Related Citations

Silent suffering: the impact of sexual health challenges on patient-clinician communication and adherence to adjuvant endocrine therapy among Black women with early-stage breast cancer.
Authors: Anderson J.N. , Paladino A.J. , Blue R. , Dangerfield D.T. , Eggly S. , Martin M.Y. , Schwartzberg L.S. , Vidal G.A. , Graetz I. .
Source: Journal Of Cancer Survivorship : Research And Practice, 2023-12-19 00:00:00.0; , .
EPub date: 2023-12-19 00:00:00.0.
PMID: 38114711
Related Citations

"I don't just say, Hi! I'm gay": Sexual Orientation Disclosures in Oncology Clinic Settings Among Sexual Minority Women Treated for Breast Cancer in the U.S. South.
Authors: Anderson J.N. , Paladino A.J. , Robles A. , Krukowski R.A. , Graetz I. .
Source: Seminars In Oncology Nursing, 2023 Aug; 39(4), p. 151452.
EPub date: 2023-06-17 00:00:00.0.
PMID: 37331879
Related Citations

The Importance of Lay Summaries for Improving Science Communication.
Authors: Goldstein C.M. , Krukowski R.A. .
Source: Annals Of Behavioral Medicine : A Publication Of The Society Of Behavioral Medicine, 2023-06-30 00:00:00.0; 57(7), p. 509-510.
PMID: 37379509
Related Citations

An examination of health care utilization during the COVID-19 pandemic among women with early-stage hormone receptor-positive breast cancer.
Authors: Paladino A.J. , Pebley K. , Kocak M. , Krukowski R.A. , Waters T.M. , Vidal G. , Schwartzberg L.S. , Curry A.N. , Graetz I. .
Source: Bmc Health Services Research, 2022-11-23 00:00:00.0; 22(1), p. 1403.
EPub date: 2022-11-23 00:00:00.0.
PMID: 36419005
Related Citations

Associations of telemedicine vs. in-person ambulatory visits and cancellation rates and 30-day follow-up hospitalizations and emergency department visits.
Authors: Kubes J.N. , Graetz I. , Wiley Z. , Franks N. , Kulshreshtha A. .
Source: Preventive Medicine Reports, 2021 Dec; 24, p. 101629.
EPub date: 2021-11-05 00:00:00.0.
PMID: 34976682
Related Citations

THRIVE intervention development: using participatory action research principles to guide a mHealth app-based intervention to improve oncology care.
Authors: Anderson J.N. , Krukowski R.A. , Paladino A.J. , Graff J.C. , Schwartzberg L. , Curry A.N. , Vidal G.A. , Jones T.N. , Waters T.M. , Graetz I. .
Source: Journal Of Hospital Management And Health Policy, 2021 Mar; 5, .
EPub date: 2021-03-25 00:00:00.0.
PMID: 34308256
Related Citations

"Nobody Will Tell You. You've Got to Ask!": An Examination of Patient-provider Communication Needs and Preferences among Black and White Women with Early-stage Breast Cancer.
Authors: Anderson J.N. , Graff J.C. , Krukowski R.A. , Schwartzberg L. , Vidal G.A. , Waters T.M. , Paladino A.J. , Jones T.N. , Blue R. , Kocak M. , et al. .
Source: Health Communication, 2020-04-26 00:00:00.0; , p. 1-12.
EPub date: 2020-04-26 00:00:00.0.
PMID: 32336140
Related Citations

THRIVE study protocol: a randomized controlled trial evaluating a web-based app and tailored messages to improve adherence to adjuvant endocrine therapy among women with breast cancer.
Authors: Paladino A.J. , Anderson J.N. , Krukowski R.A. , Waters T. , Kocak M. , Graff C. , Blue R. , Jones T.N. , Buzaglo J. , Vidal G. , et al. .
Source: Bmc Health Services Research, 2019-12-19 00:00:00.0; 19(1), p. 977.
EPub date: 2019-12-19 00:00:00.0.
PMID: 31856812
Related Citations

A qualitative exploration of race-based differences in social support needs of diverse women with breast cancer on adjuvant therapy.
Authors: Paladino A.J. , Anderson J.N. , Graff J.C. , Krukowski R.A. , Blue R. , Jones T.N. , Buzaglo J. , Kocak M. , Vidal G.A. , Graetz I. .
Source: Psycho-oncology, 2019 Mar; 28(3), p. 570-576.
EPub date: 2019-02-05 00:00:00.0.
PMID: 30636189
Related Citations

Use of a web-based app to improve breast cancer symptom management and adherence for aromatase inhibitors: a randomized controlled feasibility trial.
Authors: Graetz I. , McKillop C.N. , Stepanski E. , Vidal G.A. , Anderson J.N. , Schwartzberg L.S. .
Source: Journal Of Cancer Survivorship : Research And Practice, 2018-02-28 00:00:00.0; , .
EPub date: 2018-02-28 00:00:00.0.
PMID: 29492753
Related Citations



Back to Top